siRNAsense AS  was founded in December 2004 based on RNA interference research performed at The Biotechnology Centre of Oslo. The revolutionary discovery of RNA interference is the basis for development of a new class of drugs targeting serious diseases. siRNAsense will broaden its pipeline with new projects based on high class Scandinavian research within the field of RNA interference. Based on our experience with development of in-house drugs, we also offer services in target validation and proof-of-concept studies.

Board:
  • Dag Dvergsten (Chair)
  • Hege Anfindsen